McCormick EE, Francis BJ, Gelb AB. A new antibody apparently defining an allele of Goa (abstract). Transfusion 1965;5:369–70Search in Google Scholar
Stroup M, McCreary J. Cra, another high frequency blood group factor (abstract). Transfusion 1975;15:522.Search in Google Scholar
Daniels GL, Tohyama H, Uchikawa M. A possible null phenotype in the Cromer blood group complex. Transfusion 1982;22:362–3.10.1046/j.1537-2995.1982.22583017458.x7123631Search in Google Scholar
Yazer MH, Judd WJ, Davenport RD, et al. Case report and literature review: transient Inab phenotype and an agglutinating anti-IFC in a patient with a gastrointestinal problem. Transfusion 2006;46:1537–42.10.1111/j.1537-2995.2006.00933.x16965581Search in Google Scholar
Spring FA, Judson PA, Daniels GL, Parsons SF, Mallinson G, Anstee DJ. A human cell-surface glycoprotein that carries Cromer-related blood group antigens on erythrocytes and is also expressed on leucocytes and platelets. Immunology 1987;62:307–13.Search in Google Scholar
Telen MJ, Hall SE, Green AM, Moulds JJ, Rosse WF. Identification of human erythrocyte blood group antigens on decay-accelerating factor (DAF) and an erythrocyte phenotype negative for DAF. J Exp Med 1988;167:1993–8.10.1084/jem.167.6.199321896702455016Search in Google Scholar
Parsons SF, Spring FA, Merry AH. Evidence that Cromer-related blood group antigens are carried on decay accelerating factor (DAF) suggests that the Inab phenotype is a novel form of DAF deficiency (abstract). In: Proceedings of the XXth Congress of the International Society of Blood Transfusion. London: British Blood Transfusion Society, 1988:116.Search in Google Scholar
Lublin DM, Atkinson JP. Decay-accelerating factor: biochemistry, molecular biology, and function. Annu Rev Immunol 1989;7:35–58.10.1146/annurev.iy.07.040189.0003432469439Search in Google Scholar
Barclay AN, Brown MH, Law SKA, McKnight AJ, Tomlinson MG, van der Merwe PA. Leucocyte antigen factsbook. 2nd ed. San Diego, CA: Academic Press, 1997.Search in Google Scholar
Rey-Campos J, Rubinstein P, Rodriguez de Cordoba S. Decay-accelerating factor. Genetic polymorphism and linkage to the RCA (regulator of complement activation) gene cluster in humans. J Exp Med 1987;166:246–52.10.1084/jem.166.1.24621886462439634Search in Google Scholar
Medof ME, Lublin DM, Holers VM, et al. Cloning and characterization of cDNAs encoding the complete sequence of decay-accelerating factor of human complement. Proc Natl Acad Sci U S A 1987;84:2007–11.10.1073/pnas.84.7.20073045722436222Search in Google Scholar
Caras IW, Davitz MA, Rhee L, Weddell G, Martin DW Jr, Nussenzweig V. Cloning of decay-accelerating factor suggests novel use of splicing to generate two proteins. Nature 1987;325:545–9.10.1038/325545a02433596Search in Google Scholar
Post TW, Arce MA, Liszewski MK, Thompson ES, Atkinson JP, Lublin DM. Structure of the gene for human complement protein decay accelerating factor. J Immunol 1990;144:740–4.Search in Google Scholar
Laird-Fryer B, Dukes CV, Lawson J, Moulds JJ, Walker EM Jr, Glassman AB. Tca: A high-frequency blood group antigen. Transfusion 1983;23:124–7.10.1046/j.1537-2995.1983.23283172848.x6836691Search in Google Scholar
Levene C, Harel N, Lavie G, Greenberg S, Laird-Fryer B, Daniels GL. A “new” phenotype confirming a relationship between Cra and Tca. Transfusion 1984;24:13–15.10.1046/j.1537-2995.1984.24184122551.x6695433Search in Google Scholar
Tregellas WM. Description of a new blood group antigen, Esa (abstract). In: 18th Congress of the International Society of Blood Transfusion, Paris, 1984:163.Search in Google Scholar
Daniels G, Walthers L. Anti-IFC, an antibody made by Inab phenotype individuals. Transfusion 1986;26:117–18.10.1046/j.1537-2995.1986.26186124016.x3945998Search in Google Scholar
Petty AC, Daniels GL, Tippett P. Provisional assignment of Cromer system antigens to the short consensus repeats of decay accelerating factor (CD 55) (abstract). Transfusion 1993;33(Suppl):46S.Search in Google Scholar
Hue-Roye K, Lomas-Francis C, Belaygorod L, et al. Three new high-prevalence antigens in the Cromer blood group system. Transfusion 2007;47:1621–9.10.1111/j.1537-2995.2007.01333.xSearch in Google Scholar
Lublin DM, Kompelli S, Storry JR, Reid ME. Molecular basis of Cromer blood group antigens. Transfusion 2000;40:208–13.10.1046/j.1537-2995.2000.40020208.xSearch in Google Scholar
Telen MJ, Rao N, Lublin DM. Location of WESb on decay-accelerating factor (letter). Transfusion 1995;35:278.10.1046/j.1537-2995.1995.35395184292.xSearch in Google Scholar
Telen MJ, Rao N, Udani M, Thompson ES, Kaufman RM, Lublin DM. Molecular mapping of the Cromer blood group Cra and Tca epitopes of decay accelerating factor: toward the use of recombinant antigens in immunohematology. Blood 1994;84:3205–11.10.1182/blood.V84.9.3205.3205Search in Google Scholar
Smith KJ, Coonce LS, South SF, Troup GM. Anti-Cra: family study and survival of chromium-labeled incompatible red cells in a Spanish-American patient. Transfusion 1983;23:167–9.10.1046/j.1537-2995.1983.23283172860.xSearch in Google Scholar
Daniels G. Human blood groups. 2nd ed. Oxford: Blackwell Science, 2002.10.1002/9780470987018Search in Google Scholar
Sacks DA, Garratty G. Isoimmunization to Cromer antigen in pregnancy. Am J Obstet Gynecol 1989;161:928–9.10.1016/0002-9378(89)90754-0Search in Google Scholar
Laird-Fryer B, Dukes C, Walker EM Jr, Glassman A, Moulds JJ. Tca: a new high-incidence blood group factor (abstract). Transfusion 1980;20:631.Search in Google Scholar
Block U, Lacey P, Moulds J, Bryant L, Giandelone A, Linnemeyer D. Anti-Tcb: An antibody defining a low-incidence antigen allelic to Tca (abstract). Transfusion 1982;22:413.Search in Google Scholar
Lacey PA, Block UT, Laird-Fryer BJ, et al. Anti-Tcb, an antibody that defines a red cell antigen antithetical to Tca. Transfusion 1985;25:373–6.10.1046/j.1537-2995.1985.25485273820.x4024236Search in Google Scholar
Law J, Judge A, Covert P, Lewis N, Sabo B, McCreary M. A new low-frequency factor proposed to be the product of an allele to Tca (abstract). Transfusion 1982;22:413.Search in Google Scholar
Levene C, Harel N, Kende G, Papo S, Bradford MF, Daniels GL. A second Dr(a–) proposita with anti-Dra and a family with the Dr(a–) phenotype in two generations. Transfusion 1987;27:64–5.10.1046/j.1537-2995.1987.27187121478.x3810829Search in Google Scholar
Daniels G. Cromer-related antigens—blood group determinants on decay-accelerating factor. Vox Sang 1989;56:205–11.10.1111/j.1423-0410.1989.tb02030.x2474898Search in Google Scholar
Reid ME, Mallinson G, Sim RB, et al. Biochemical studies on red blood cells from a patient with the Inab phenotype (decay-accelerating factor deficiency). Blood 1991;78:3291–7.10.1182/blood.V78.12.3291.3291Search in Google Scholar
Lublin DM, Mallinson G, Poole J, et al. Molecular basis of reduced or absent expression of decay-accelerating factor in Cromer blood group phenotypes. Blood 1994;84:1276–82.10.1182/blood.V84.4.1276.1276Search in Google Scholar
Daniels GL, Green CA, Mallinson G, et al. Decay-accelerating factor (CD55) deficiency phenotypes in Japanese. Transfus Med 1998;8:141–7.10.1046/j.1365-3148.1998.00145.x9675792Search in Google Scholar
Uchikawa M, Tsuneyama H, Wang L, et al. Rare Cromer blood group phenotypes detected in Japanese (abstract). In: 24th Congress of the International Society of Blood Transfusion (ISBT), Makuhari Messe, Japan, 1996;143.Search in Google Scholar
Lublin DM, Thompson ES, Green AM, Levene C, Telen MJ. Dr(a–) polymorphism of decay accelerating factor. Biochemical, functional, and molecular characterization and production of allele-specific transfectants. J Clin Invest 1991;87:1945–52.10.1172/JCI1152202969461710232Search in Google Scholar
Nowicki B, Moulds J, Hull R, Hull S. A hemagglutinin of uropathogenic Escherichia coli recognizes the Dr blood group antigen. Infect Immun 1988;56:1057–60.10.1128/iai.56.5.1057-1060.19882597612895740Search in Google Scholar
Reid ME, Marfoe RA, Mueller AL, Arndt PA, Sausais L, Spruell P. A second example of anti-Esa, an antibody to a high-incidence Cromer antigen. Immunohematology 1996;12:112–14.10.21307/immunohematology-2019-760Search in Google Scholar
Wang L, Uchiwawa M, Tsuneyama H, Tokunaga K, Tadokoro K, Juji T. Molecular cloning and characterization of decay-accelerating factor deficiency in Cromer blood group Inab phenotype. Blood 1998;91:680–4.10.1182/blood.V91.2.680Search in Google Scholar
Uchikawa M, Tsuneyama H, Ogasawara K, et al. Another example of Inab phenotype in Japanese and production of human monoclonal anti-DAF (abstract). Vox Sang 2004;87(S3):41.Search in Google Scholar
Hue-Roye K, Powell VI, Patel G, et al. Novel molecular basis of an Inab phenotype. Immunohematology 2005;21:53–5.10.21307/immunohematology-2019-393Search in Google Scholar
Walthers L, Salem M, Tessel J, Laird-Fryer B, Moulds JJ. The Inab phenotype: another example found (abstract). Transfusion 1983;23:423.Search in Google Scholar
Lin RC, Herman J, Henry L, Daniels GL. A family showing inheritance of the Inab phenotype. Transfusion 1988;28:427–9.10.1046/j.1537-2995.1988.28588337329.x3420669Search in Google Scholar
Daniels GL. Blood group antigens of high frequency: a serological and genetical study (thesis). London: MRC Blood Group Unit, University College, 1980.Search in Google Scholar
Rosse WF, Hoffman S, Campbell M, Borowitz M, Moore JO, Parker CJ. The erythrocytes in paroxysmal nocturnal haemoglobinuria of intermediate sensitivity to complement lysis. Br J Haematol 1991;79:99–107.10.1111/j.1365-2141.1991.tb08014.x1716964Search in Google Scholar
Merry AH, Rawlinson VI, Uchikawa M, Daha MR, Sim RB. Studies on the sensitivity to complement-mediated lysis of erythrocytes (Inab phenotype) with a deficiency of DAF (decay accelerating factor). Br J Haematol 1989;73:248–53.10.1111/j.1365-2141.1989.tb00260.x2479410Search in Google Scholar
Rosse WF. Phosphatidylinositol-linked proteins and paroxysmal nocturnal hemoglobinuria. Blood 1990;75:1595–601.10.1182/blood.V75.8.1595.1595Search in Google Scholar
Medof ME, Walter EI, Rutgers JL, Knowles DM, Nussenzweig V. Identification of the complement decay-accelerating factor (DAF) on epithelium and glandular cells and in body fluids. J Exp Med 1987;165:848–64.10.1084/jem.165.3.84821882952434600Search in Google Scholar
Matthes T, Tullen E, Poole J, et al. Acquired and transient RBC CD55 deficiency (Inab phenotype) and anti-IFC. Transfusion 2002;42:1448–57.10.1046/j.1537-2995.2002.00214.x12421218Search in Google Scholar
Banks J, Poole J, Prowse C, Warke N, Ekermo B, Hilden J-O. Transient loss of Cromer antigens and anti-IFC in a patient with chronic lymphatic leukemia. Vox Sang 2004;87(S3):37.Search in Google Scholar
Sistonen P, Nevanlinna HR, Virtaranta-Knowles K, et al. WES, a ‘new’ infrequent blood group antigen in Finns. Vox Sang 1987;52:111–14.10.1111/j.1423-0410.1987.tb03003.x3300022Search in Google Scholar
Copeland TR, Smith JH, Wheeling RM, Rudolph MG. The incidence of WESa in 3,072 donors in the United States. Immunohematology 1991;7:76–7.10.21307/immunohematology-2019-1016Search in Google Scholar
Daniels GL, Green CA, Darr FW, Anderson H, Sistonen P. A ‘new’ Cromer-related high frequency antigen probably antithetical to WES. Vox Sang 1987;53:235–8.10.1111/j.1423-0410.1987.tb05073.x3439100Search in Google Scholar
Daniels GL, Okubo Y, Yamaguchi H, Seno T, Ikuta M. UMC, another Cromer-related blood group antigen. Transfusion 1989;29:794–7.10.1046/j.1537-2995.1989.29990070184.x2480010Search in Google Scholar
Storry JR, Sausais L, Hue-Roye K, et al. GUTI: a new antigen in the Cromer blood group system. Transfusion.2003;43:340–4.10.1046/j.1537-2995.2003.00319.x12675719Search in Google Scholar
Banks J, Poole J, Ahrens N, et al. SERF: a new antigen in the Cromer blood group system. Transfus Med 2004;14:313–18.10.1111/j.0958-7578.2004.00519.x15285728Search in Google Scholar
Palacajornsuk P, Hue-Roye K, Nathalang O, Tantimavanich S, Bejrachandra S, Reid ME. Analysis of SERF in Thai blood donors. Immunohematology 2005;21:66–9.10.21307/immunohematology-2019-396Search in Google Scholar
Reid ME, Green CA, Hoffer J, Øyen R. Effect of pronase on high-incidence blood group antigens and the prevalence of antibodies to pronase-treated erythrocytes. Immunohematology 1996;12:139–42.10.21307/immunohematology-2019-767Search in Google Scholar
Judd WJ, Steiner EA, Miske V. Adsorption of anti-Cra by human platelet concentrates (letter). Transfusion 1991;31:286.10.1046/j.1537-2995.1991.31391165184.x2003331Search in Google Scholar
Schanfield MS, Schoeppner SL, Stevens JO. New approaches to detecting clinically significant antibodies in the laboratory. In: Sandler SG, Nusbacher J, Schanfield MS, eds. Immunobiology of the erythrocyte. New York, NY: AR Liss, 1980:305–23.Search in Google Scholar
Garratty G, Nance SJ. Correlation between in vivo hemolysis and the amount of red cell-bound IgG measured by flow cytometry. Transfusion 1990;30:617–21.10.1046/j.1537-2995.1990.30790385519.x2402775Search in Google Scholar
McSwain B, Robins C. A clinically significant anti-Cra. Transfusion 1988;28:289–90.10.1046/j.1537-2995.1988.28388219165.x3368942Search in Google Scholar
Gorman MI, Glidden HM, Behzad O. Another example of anti-Tca (abstract). Transfusion 1981;21:579.10.1046/j.1537-2995.1981.21582040824.x7292587Search in Google Scholar
Ross DG, McCall L. Transfusion significance of anti-Cra (letter). Transfusion 1985;25:84.10.1046/j.1537-2995.1985.25185116515.x3918364Search in Google Scholar
Anderson G, Gray LS, Mintz PD. 51 Cr-radiolabeled red cell survival in a patient with anti-Tca (abstract). Transfusion 1987;27:546.Search in Google Scholar
Whitsett CF, Oxendine SM. Survival studies with another example of anti-Cra. Transfusion 1991;31:782–4.10.1046/j.1537-2995.1991.31892023513.x1926327Search in Google Scholar
Kowalski MA, Pierce SR, Edwards RL, Ethirajan S, Ryan K, Livergood MP. Hemolytic transfusion reaction due to anti-Tca. Transfusion 1999;39:948–50.10.1046/j.1537-2995.1999.39090948.x10533820Search in Google Scholar
Reid ME, Ellisor SS, Dean WD. Elution of anti-Cra. Superiority of the digitonin-acid elution method. Transfusion 1985;25:172–3.10.1046/j.1537-2995.1985.25285169215.x3984011Search in Google Scholar
Holmes CH, Simpson KL, Wainwright SD, et al. Preferential expression of the complement regulatory protein decay accelerating factor at the fetomaternal interface during human pregnancy. J Immunol 1990;144:3099–105.Search in Google Scholar
Weber SL, Bryant BJ, Indrikovs AJ. Sequestration of anti-Cra in the placenta: serologic demonstration by placental elution. Transfusion 2005;45:1327–30.10.1111/j.1537-2995.2005.00205.x16078921Search in Google Scholar
Reid ME, Chandrasekaran V, Sausais L, Pierre J, Bullock R. Disappearance of antibodies to Cromer blood group system antigens during mid pregnancy. Vox Sang 1996;71:48–50.10.1046/j.1423-0410.1996.7110048.x8837357Search in Google Scholar
Dickson AC, Guest C, Jordon M, Banks J, Kumpel BM. Case report: anti-Cra in pregnancy. Immunohematology 1995;11:14–17.10.21307/immunohematology-2019-780Search in Google Scholar
Rahimi-Levene N, Kornberg A, Siegel G, et al. Persistent anti-Dra in two pregnancies. Immunohematology 2005;21:126–8.10.21307/immunohematology-2019-405Search in Google Scholar
